Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Ultragenyx

Healthcare US RARE

22.41USD
0.63(2.89%)

Last update at 2026-06-03T20:00:00Z

Day Range

21.8022.61
LowHigh

52 Week Range

31.5254.98
LowHigh

Fundamentals

  • Previous Close 21.78
  • Market Cap3270.46M
  • Volume1798324
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-550.83501M
  • Revenue TTM442.59M
  • Revenue Per Share TTM5.75
  • Gross Profit TTM -370.78000M
  • Diluted EPS TTM-7.75

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -701.72500M -452.98100M -185.35900M -399.44400M -197.09700M
Minority interest - - - - -
Net income -707.42100M -454.02500M -186.56600M -402.72700M -197.61100M
Selling general administrative 278.14M 219.98M 182.93M 161.52M 127.72M
Selling and marketing expenses - - - - -
Gross profit 335.01M 335.40M 264.90M 94.71M 50.35M
Reconciled depreciation 18.22M 13.24M 12.26M 8.54M 19.54M
Ebit -648.91900M -381.73700M -330.11600M -424.17300M -561.23300M
Ebitda -639.41100M -381.49600M -322.47100M -411.72200M -541.69500M
Depreciation and amortization 9.51M 0.24M 7.64M 12.45M 19.54M
Non operating income net other 9.51M 0.24M 7.64M 12.45M 174.28M
Operating income -648.91900M -381.73700M -330.11600M -424.17300M -371.37300M
Other operating expenses 1012.25M 733.14M 601.15M 527.89M 422.87M
Interest expense 43.02M 29.42M 33.29M 1.14M 0.00000M
Tax provision 5.70M 1.04M 1.21M 3.28M 0.51M
Interest income 11.07M 1.93M 7.04M 13.24M 9.54M
Net interest income -31.94100M -29.42200M -26.25300M 12.10M 9.54M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 5.70M 1.04M 1.21M 3.28M 0.51M
Total revenue 363.33M 351.41M 271.03M 103.71M 51.49M
Total operating expenses 983.93M 717.13M 595.02M 518.88M 421.72M
Cost of revenue 28.32M 16.01M 6.13M 9.01M 1.15M
Total other income expense net -52.80600M -71.24400M 144.76M 24.73M 174.28M
Discontinued operations - - - - -
Net income from continuing ops -707.42100M -454.02500M -186.56600M -402.72700M -197.61100M
Net income applicable to common shares -707.42100M -454.02500M -186.56600M -402.72700M -197.61100M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 1491.01M 1545.44M 1522.40M 1759.56M 1135.50M
Intangible assets 166.27M 160.10M 130.79M 131.11M 129.00M
Earning assets - - - - -
Other current assets -777.11000M 68.93M -187.18800M 47.12M 46.22M
Total liab 1215.60M 1192.95M 599.84M 605.18M 481.73M
Total stockholder equity 275.41M 352.49M 922.56M 1154.38M 653.76M
Deferred long term liab - 31.67M 33.31M 33.31M 33.31M
Other current liab 29.24M 204.68M 145.56M 108.49M 83.19M
Common stock 0.08M 0.07M 0.07M 0.07M 0.06M
Capital stock 0.08M 0.07M 0.07M 0.07M 0.06M
Retained earnings -3387.66100M -2781.02200M -2073.60100M -1619.57600M -1433.01000M
Other liab - 911.93M 387.56M 376.32M 348.68M
Good will 44.41M 44.41M 44.41M 44.41M 44.41M
Other assets - 16.85M 20.56M 8.81M 3.47M
Cash 213.58M 132.94M 307.58M 713.53M 433.58M
Cash and equivalents - - - - -
Total current liabilities 280.44M 261.21M 181.37M 189.61M 103.30M
Current deferred revenue 196.49M 1.48M 7.61M 59.22M -
Net debt -170.41500M -101.35100M -265.61400M -665.29900M -396.59200M
Short term debt 12.60M 11.78M 11.07M 8.98M 7.24M
Short long term debt - - - - -
Short long term debt total 43.17M 31.59M 41.97M 48.23M 36.99M
Other stockholder equity 3662.35M 3140.02M 2997.50M 2773.20M 2086.86M
Property plant equipment - 259.73M 141.25M 73.52M 74.68M
Total current assets 732.18M 883.90M 856.60M 1295.30M 851.02M
Long term investments 199.90M 154.50M 258.93M 10.51M 32.93M
Net tangible assets - 147.98M 758.40M 978.86M 480.36M
Short term investments 363.62M 614.82M 432.61M 488.01M 321.65M
Net receivables 73.39M 40.45M 28.43M 23.09M 32.84M
Long term debt - - - - -
Inventory 33.97M 26.77M 16.23M 13.05M 11.55M
Accounts payable 42.11M 43.27M 17.14M 12.92M 12.87M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.65M -6.57300M -1.40400M 0.69M -0.14700M
Additional paid in capital - - - - -
Common stock total equity - 0.07M 0.07M 0.07M 0.06M
Preferred stock total equity - - - - -
Retained earnings total equity - -2781.02200M -2073.60100M -1619.57600M -1433.01000M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 51.73M 16.85M 20.56M 8.81M 3.47M
Deferred long term asset charges - - - - -
Non current assets total 758.83M 661.54M 665.79M 464.25M 284.48M
Capital lease obligations 43.17M 31.59M 41.97M 48.23M 36.99M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -291.65200M -201.18000M -209.50300M 11.79M -199.57700M
Change to liabilities 78.21M -25.17900M 93.42M 15.45M 2.36M
Total cashflows from investing activities -291.65200M -195.37200M -179.12100M -13.03900M -33.33100M
Net borrowings - - - - -
Total cash from financing activities 501.21M 118.55M 600.27M 679.31M 336.85M
Change to operating activities 3.80M -29.50800M 2.75M -6.84000M -14.28500M
Net income -707.42100M -454.02500M -186.56600M -402.72700M -197.61100M
Change in cash -171.98400M -416.70900M 290.05M 320.72M 12.48M
Begin period cash flow 309.58M 726.29M 436.24M 115.53M 103.04M
End period cash flow 137.60M 309.58M 726.29M 436.24M 115.53M
Total cash from operating activities -380.46500M -338.69500M -132.22000M -345.38300M -290.56600M
Issuance of capital stock 0.00000M 78.94M 511.21M 355.24M 309.02M
Depreciation 18.22M 13.24M 12.26M 8.54M 19.54M
Other cashflows from investing activities -95.77500M 78.90M 74.29M 11.79M 170.32M
Dividends paid - - - - -
Change to inventory -9.70100M -3.11700M -1.34600M -4.45100M -5.28300M
Change to account receivables -12.06800M -5.43200M 9.84M -20.10400M -7.58300M
Sale purchase of stock 10.81M 40.10M 524.85M 340.24M 298.80M
Other cashflows from financing activities 490.39M 39.61M 89.06M 324.06M 27.83M
Change to netincome 74.80M 0.23M 0.95M 83.24M -85.06200M
Capital expenditures 146.12M 73.09M 43.91M 24.83M 4.08M
Change receivables -12.06800M -5.43200M 9.84M -20.10400M -7.58300M
Cash flows other operating 253.00M 103.80M 31.80M -3.66600M -14.28500M
Exchange rate changes - - - - -
Cash and cash equivalents changes -170.90900M -415.51500M 288.93M 320.88M 12.96M
Change in working capital 60.23M -63.23600M 104.66M -15.94300M -24.79000M
Stock based compensation 130.38M 104.95M 85.73M 82.00M 80.11M
Other non cash items 119.76M 11.71M 21.46M 1.69M -0.15600M
Free cash flow -526.58800M -411.78800M -176.12500M -370.21500M -294.64200M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
RARE
Ultragenyx		 0.63 2.89% 22.41 - - 8.91 14.05 7.68 -6.4589
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

Ultragenyx

60 Leveroni Court, Novato, CA, United States, 94949

Key Executives

Name Title Year Born
Dr. Emil D. Kakkis M.D., Ph.D. Founder, Pres, CEO & Director 1960
Mr. John Richard Pinion II Chief Quality Operations Officer & Exec. VP of Translational Sciences 1966
Dr. Camille L. Bedrosian M.D. Chief Medical Officer & Exec. VP 1953
Mr. Erik Harris Exec. VP & Chief Commercial Officer 1970
Mr. Theodore A. Huizenga Sr. VP, Corp. Controller & Principal Accounting Officer 1971
Mr. Dennis Karl Huang Chief Technical Operations Officer & Exec. VP 1965
Ms. Danielle Keatley Sr. Director of Investor Relations & Corp. Communications NA
Ms. Karah Herdman Parschauer J.D. Chief Legal Officer & Exec. VP 1978
Mr. Ernie W. Meyer Chief HR Officer & Exec. VP 1964
Mr. Thomas R. Kassberg Chief Bus. Officer & Exec. VP 1960

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.